Liquidia Corp has recently released its 10-K report, revealing key insights into its financial performance and operations. The biopharmaceutical company is focused on developing, manufacturing, and commercializing products for unmet patient needs in the United States, with its lead product candidates including YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Liquidia Corp also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion, and is developing L606, an investigational liposomal formulation of treprostinil for the treatment of PAH and PH-ILD.
In its 10-K report, Liquidia Corp discusses the results of operations for the years ended December 31, 2025, and 2024, highlighting significant trends and material changes in its financial position and operating results. The company incurred a net loss of $68.9 million in 2025, compared to $128.3 million in 2024 and $78.5 million in 2023. As of December 31, 2025, Liquidia Corp had an accumulated deficit of $626.3 million. The company expects to continue incurring significant expenses as it continues the commercialization of YUTREPIA and advances its product candidates through clinical trials and seeks regulatory approval.
Liquidia Corp generated $148.3 million in product sales, net, in 2025, following the FDA approval of YUTREPIA in May 2025 for the treatment of PAH and PH-ILD. The company also reported service revenue, net, of $10.0 million for 2025, primarily related to the Promotion Agreement. However, service revenue decreased by 28% compared to the previous year, primarily due to lower sales volumes.
Cost of product sales for 2025 was $8.8 million, directly related to the sales of YUTREPIA, while cost of service revenue was $4.4 million, reflecting a lower allocation of costs related to the commercial field force for Treprostinil Injection. Research and development expenses decreased by 18% to $39.3 million in 2025, primarily due to lower personnel expenses, stock-based compensation, and facilities and infrastructure expenses as the company shifted activities from research and development to the commercialization of YUTREPIA.
Following these announcements, the company's shares moved -2.22%, and are now trading at a price of $37.93. For the full picture, make sure to review Liquidia Corp's 10-K report.
